This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Qiagen (QGEN) Up 1.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base
by Zacks Equity Research
QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.
QIAGEN (QGEN) Earns Notable Recognitions in Sustainability
by Zacks Equity Research
QIAGEN (QGEN) achieves the ACT Label for new eco-friendly QIAwave products and the first My Green Lab Platinum certification.
QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands
by Zacks Equity Research
QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences
by Zacks Equity Research
QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.
QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.
QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes
by Zacks Equity Research
QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.
Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Qiagen (QGEN) Up 9.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Expands Sample Technologies Line With New Launch
by Zacks Equity Research
QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.
QIAGEN (QGEN) Launches QIAcuity Kits and Software Update
by Zacks Equity Research
QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.
QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research
by Zacks Equity Research
QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.
QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays
by Zacks Equity Research
QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.
QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down
by Zacks Equity Research
In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.
Qiagen (QGEN) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2.04% and 0.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Techne (TECH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.
QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay
by Zacks Equity Research
QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.